Name (Synonyms) | Correlation | |
---|---|---|
drug1061 | Povidone-Iodine 0.5% Wiki | 1.00 |
drug1062 | Povidone-Iodine 2% Wiki | 1.00 |
drug145 | BCG vaccine Wiki | 0.71 |
drug1016 | Placebo Wiki | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
D006331 | Heart Diseases NIH | 0.71 |
D003327 | Coronary Disease NIH | 0.58 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.50 |
D008173 | Lung Diseases, Obstructive NIH | 0.41 |
D014777 | Virus Diseases NIH | 0.13 |
D007239 | Infection NIH | 0.07 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."
Description: Nasopharyngeal swabs will be obtained and quantitative polymerase chain reaction (PCR) testing will be performed to determine the viral load in the nasopharynx
Measure: Mean change in viral titers of SARS-CoV-2 Time: Baseline, Day 3, Day 6, and Day 9Description: Adverse effects of interest include: Nasal burning/pain Headaches Ear pain Sneezing Nose bleeds
Measure: Frequency of adverse effects of interest after nasal sprays Time: Up to 9 daysDescription: Symptoms of interest include: Fever Fatigue Change in smell Change in taste Nasal obstruction
Measure: Frequency of symptoms related to SARS-CoV-2 Time: Up to 9 days